List of Excipients in Branded Drug METHOCARBAMOL AND ASPIRIN

« Back to Dashboard

Generic Drugs Containing METHOCARBAMOL AND ASPIRIN

Company	Ingredient	NDC	Excipient
Jerome Stevens Pharmaceuticals Inc	methocarbamol and aspirin	50564-490	CELLULOSE, MICROCRYSTALLINE
Jerome Stevens Pharmaceuticals Inc	methocarbamol and aspirin	50564-490	CROSCARMELLOSE SODIUM
Jerome Stevens Pharmaceuticals Inc	methocarbamol and aspirin	50564-490	MAGNESIUM STEARATE
Jerome Stevens Pharmaceuticals Inc	methocarbamol and aspirin	50564-490	POVIDONE
Jerome Stevens Pharmaceuticals Inc	methocarbamol and aspirin	50564-490	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in METHOCARBAMOL AND ASPIRIN?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	MAGNESIUM STEARATE
1	POVIDONE
1	SILICON DIOXIDE

Methocarbamol and Aspirin Excipient Strategy and Commercial Opportunities

Last updated: October 10, 2026

Methocarbamol-aspirin fixed-dose tablets offer a low-barrier generic and reformulation opportunity, but commercial success depends on moisture control, aspirin stability, tablet-size management, and a clear regulatory pathway. The historical combination, marketed in products such as Robaxisal and Robaxisal-750, used methocarbamol as a centrally acting muscle relaxant and aspirin as an analgesic. The active ingredients are old, inexpensive, and broadly available, which limits protection from active-ingredient patents. Value is more likely to come from formulation performance, manufacturing reliability, dosage convenience, and channel positioning.

The strongest development concept is a low-moisture, immediate-release, film-coated tablet using a nonalkaline excipient system. A bilayer or capsule-based presentation may create additional differentiation but would face higher manufacturing and regulatory costs.

What is the methocarbamol and aspirin drug combination?

Methocarbamol and aspirin have been combined in prescription products for painful musculoskeletal conditions. Historical strengths included:

Product type	Methocarbamol	Aspirin	Dosage form
Robaxisal-type tablet	500 mg	325 mg	Immediate-release tablet
Robaxisal-750-type tablet	750 mg	325 mg	Immediate-release tablet

Methocarbamol is a centrally acting skeletal-muscle relaxant. Aspirin provides analgesic and anti-inflammatory activity. The combination is intended for short-term treatment of painful muscle injury or spasm rather than chronic use.

Aspirin creates the primary formulation risk. It is susceptible to hydrolysis in the presence of moisture, producing salicylic acid and acetic acid. The degradation pathway can affect assay, odor, tablet appearance, dissolution, and impurity levels. Methocarbamol adds a substantial dose burden, particularly in the 750-mg strength.

Historical labeling identifies common tablet excipients such as starch, povidone, talc, magnesium stearate, colloidal silicon dioxide, and coloring agents, although the exact composition depends on the manufacturer and strength. Current inactive-ingredient decisions should be based on the target reference product and FDA Inactive Ingredient Database rather than historical formulations alone (FDA, n.d.-a).

What excipients are most suitable for methocarbamol and aspirin tablets?

A suitable excipient system should support direct compression or low-moisture granulation, preserve aspirin stability, deliver rapid release, and limit tablet weight.

Recommended excipient functions

Formulation function	Preferred excipient strategy	Primary rationale
Diluent	Anhydrous dibasic calcium phosphate, microcrystalline cellulose, or low-moisture lactose selected cautiously	Controls tablet size and supports compressibility
Binder	Povidone or dry binder-grade polymer	Avoids water-intensive processing
Disintegrant	Crospovidone or low-substituted hydroxypropyl cellulose	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow at high drug loading
Lubricant	Magnesium stearate at controlled concentration	Reduces ejection force without excessive dissolution delay
Moisture control	Low-moisture excipient grades and high-barrier packaging	Limits aspirin hydrolysis
Coating	Immediate-release film coat with low water exposure	Improves swallowability, identification, and handling
Colorant	Iron oxide or permitted lake pigments	Provides product differentiation and light protection

Anhydrous excipients are generally more attractive than hydrated materials for an aspirin-containing product. Lactose monohydrate, hydrated salts, and hygroscopic polymers are not automatically unsuitable, but they require tighter moisture specifications and stability justification.

Alkaline excipients require particular scrutiny. Aspirin can degrade more rapidly under conditions that promote hydrolysis or increase local pH. Calcium carbonate, magnesium carbonate, sodium bicarbonate, and strongly basic buffering systems should not be included without formulation-specific stability data.

Why direct compression is commercially attractive

Direct compression minimizes water exposure and reduces manufacturing complexity. It can also shorten development time and simplify scale-up. The main challenge is uniform distribution because the formulation contains a high mass of methocarbamol and a lower mass of aspirin. Particle-size matching, ordered mixing, segregation control, and blend uniformity are critical.

A dry-granulation process is a viable alternative when the powder blend has inadequate flow or compactability. Roller compaction avoids aqueous exposure but can increase fines, alter tablet tensile strength, and affect dissolution. Wet granulation is less attractive because residual moisture can accelerate aspirin degradation unless the process is tightly controlled.

How should aspirin stability drive excipient selection?

Aspirin stability should determine the development strategy rather than being treated as a final packaging issue.

The development program should evaluate:

1. Water activity and residual moisture in each excipient.
2. Microenvironmental pH after compression.
3. Aspirin hydrolysis and salicylic-acid formation.
4. Acetic-acid odor under accelerated conditions.
5. Tablet hardness, friability, and dissolution after aging.
6. Packaging performance under high humidity.
7. Interaction between aspirin and magnesium stearate.
8. Stability after bottle opening or repeated-dose use.

A low-moisture formulation should be paired with high-barrier packaging. Alu-Alu blister packaging provides stronger moisture protection than standard PVC blistering. High-density polyethylene bottles with induction seals and desiccants can also be effective, but the closure system must be validated under the intended distribution climate.

An opaque or light-protective package may reduce appearance changes and support product differentiation. The commercial tradeoff is cost. A generic product sold through retail pharmacies may favor a bottle, while a premium hospital or specialty product may justify high-barrier blister packaging.

What formulation patents could protect methocarbamol and aspirin products?

The active ingredients are old, so the main patent opportunities are formulation-specific rather than composition-of-matter claims.

Potential claim areas include:

• Low-moisture immediate-release tablets.
• Specific excipient ratios that improve aspirin stability.
• Bilayer tablets separating methocarbamol and aspirin.
• Protective film coatings with defined water-vapor transmission rates.
• Unit-dose blister systems.
• Reduced-size high-load tablets.
• Taste-masked or orally disintegrating presentations.
• Modified-release methocarbamol with immediate-release aspirin.
• Manufacturing processes that reduce aspirin degradation.
• Impurity-control specifications linked to a defined process.

A basic tablet containing known strengths of methocarbamol and aspirin is unlikely to create strong, durable patent protection without an unexpected technical result. A patent strategy would need comparative data showing a measurable improvement, such as lower salicylic-acid formation, better dissolution after humidity exposure, reduced tablet weight, or improved patient adherence.

A formulation patent should be paired with trade-secret protection for blending order, granulation endpoint, compression settings, coating parameters, and packaging controls. Process know-how may be commercially more valuable than a narrow formulation claim.

What is the Orange Book and FDA regulatory status of methocarbamol-aspirin products?

Methocarbamol-aspirin products have historically been prescription products. The regulatory pathway for a current generic depends on the status of the reference listed drug, the relevant strength, and whether the product remains approved and listed in FDA databases.

Regulatory issue	Commercial implication
Approved reference product available	Potential ANDA pathway, subject to product-specific FDA requirements
Reference product discontinued for commercial reasons	May still support an ANDA if FDA maintains the approval for safety or regulatory purposes
No suitable reference listed drug	505(b)(2) or other pathway may be required
New dosage form or modified release	Greater clinical and CMC requirements
OTC positioning	Requires a separate monograph or approval strategy and raises aspirin safety concerns
Combination product	Must demonstrate pharmaceutical equivalence and appropriate labeling

The Orange Book should be reviewed for the specific strength, dosage form, reference listed drug, patents, and exclusivity entries. FDA’s product-specific guidance and ANDA database should also be checked before selecting a development path (FDA, n.d.-b; FDA, n.d.-c).

A developer should not assume that an old marketed brand automatically creates a straightforward ANDA route. The critical questions are whether the reference product is approved, whether the proposed product matches its strength and dosage form, and whether FDA has identified product-specific bioequivalence requirements.

When does methocarbamol and aspirin lose exclusivity?

The active ingredients have long been off patent. Commercial exclusivity is therefore more likely to depend on the reference product’s regulatory history, any later formulation patents, and market availability.

Exclusivity category	Expected relevance
Active-ingredient patent	Low; methocarbamol and aspirin are established compounds
Basic combination patent	Potentially expired or difficult to enforce if based on old formulations
Formulation patent	Possible for a new delivery system or stability solution
Method-of-use patent	Possible but generally limited for an old, established combination
Regulatory exclusivity	Must be confirmed from current FDA records
Trademark protection	May remain relevant even when patent protection is absent
Trade secrets	Relevant to process controls and packaging performance

A Paragraph IV challenge would matter only if an ANDA applicant relies on a reference product with listed patents. The applicant would need to certify that the relevant patent is invalid, unenforceable, or not infringed. Without current Orange Book records and patent-listing data for the target reference product, no specific Paragraph IV exposure or litigation date should be treated as established.

What commercial opportunities exist for methocarbamol and aspirin?

Low-cost generic immediate-release tablets

The most direct opportunity is a generic version of a historical 500/325-mg or 750/325-mg tablet. The product could compete on pharmacy availability, manufacturing reliability, and supply continuity. Margin potential would likely be limited because both active ingredients are inexpensive and the product has no obvious exclusivity barrier.

High-barrier packaged product

A formulation marketed with robust stability data and high-barrier packaging could target pharmacies, hospitals, and wholesalers that value longer shelf life and reduced degradation risk. The opportunity is operational rather than premium-brand driven.

Unit-dose blister packaging

Unit-dose blisters can support institutional dispensing, medication adherence, and inventory control. This format may be attractive where aspirin-containing products are administered for defined short courses.

Smaller or easier-to-swallow tablet

The combined active load is approximately 825 mg in the 500/325-mg strength and 1,075 mg in the 750/325-mg strength before excipients. A single tablet may be large. A high-density formulation, bilayer tablet, or split-dose presentation could address swallowability, but any change in dosage form or dosing instructions may increase regulatory complexity.

Private-label and contract manufacturing

The product is suitable for private-label pharmacy, regional generic, and contract-manufacturing arrangements. A manufacturer with validated low-moisture processing and packaging capability could offer the product as part of a broader musculoskeletal-pain portfolio.

Combination-product lifecycle management

Potential extensions include:

• A lower-dose aspirin version where clinically and regulatorily justified.
• A film-coated tablet with improved handling.
• A bilayer tablet separating the two actives.
• A package configuration optimized for short treatment courses.
• A co-pack containing the combination and patient instructions.
• A modified-release product, although this would require a stronger clinical and bioequivalence rationale.

How strong is the patent estate for methocarbamol and aspirin?

The core patent estate is likely weak relative to newer small-molecule products. Methocarbamol and aspirin are mature active ingredients, and the historical combination is not likely to support meaningful composition-of-matter protection today.

The stronger barriers are:

• Regulatory uncertainty around the reference product.
• Formulation development for aspirin stability.
• Manufacturing scale-up.
• Packaging qualification.
• Bioequivalence execution.
• Supply-chain reliability.
• Product liability and aspirin labeling requirements.
• Brand recognition held by historical product names.

A new applicant could potentially obtain narrow formulation claims, but commercial defensibility would depend on claim breadth and the ease with which competitors could design around the excipient ratios, coating composition, or package configuration.

What generic launch risks exist?

The principal launch risks are technical and commercial rather than patent-driven.

Risk	Severity	Mitigation
Aspirin hydrolysis	High	Low-moisture excipients, controlled processing, high-barrier packaging
Tablet weight and swallowability	Medium to high	High-density formulation, compression optimization
Blend segregation	Medium	Particle-size control and validated mixing
Dissolution delay from lubricant	Medium	Optimize magnesium stearate level and blending time
Reference-product uncertainty	High	Confirm current FDA pathway and product-specific requirements
Low market price	High	Secure efficient manufacturing and differentiated packaging
Limited demand	Medium	Use institutional, private-label, and portfolio channels
Aspirin-related safety concerns	Medium	Accurate labeling, controlled duration, risk communication

How does methocarbamol and aspirin compare with competing products?

Product category	Main advantage	Main limitation
Methocarbamol alone	Avoids aspirin contraindications and interactions	Lacks aspirin analgesic component
Aspirin alone	Low cost and broad analgesic familiarity	Does not provide muscle-relaxant activity
Ibuprofen-based combinations	Strong analgesic positioning	Gastrointestinal, renal, and cardiovascular risks
Acetaminophen-based combinations	Avoids aspirin platelet effects	Hepatic safety limits and different anti-inflammatory profile
Methocarbamol-aspirin	One-tablet combination and established use history	Large tablet, aspirin stability, and safety restrictions

A methocarbamol-aspirin product should not be positioned as a broad chronic-pain therapy. Its commercial niche is short-term musculoskeletal pain where a muscle relaxant and analgesic are prescribed together and aspirin is clinically appropriate.

Key Takeaways

• The best initial product is a low-moisture, immediate-release, film-coated tablet.
• Aspirin hydrolysis should control excipient selection, processing, and packaging.
• Direct compression or dry granulation is preferable to aqueous wet granulation.
• Anhydrous and low-moisture excipients are strategically attractive.
• The core active-ingredient patent estate is weak because both drugs are mature.
• Formulation patents require comparative stability or performance data.
• The commercial opportunity is primarily generic, private-label, institutional, or contract-manufactured.
• The most important regulatory task is confirming the current reference listed drug and ANDA pathway.
• High-barrier packaging and reliable shelf life can provide more practical differentiation than a narrow formulation patent.
• Generic launch risk is driven more by stability, regulatory reference-product status, and price erosion than by active-ingredient patent litigation.

FAQs

Can methocarbamol and aspirin be formulated as an orally disintegrating tablet?

Yes, but the high combined active load makes tablet-size reduction difficult. An orally disintegrating product would require careful control of moisture, taste, mechanical strength, and aspirin stability.

Is magnesium stearate compatible with aspirin in a combination tablet?

It can be used, but concentration, grade, blending time, and local microenvironment should be evaluated. Excessive lubrication may slow dissolution and can complicate stability assessment.

Would a bilayer methocarbamol-aspirin tablet be patentable?

Potentially, but a bilayer structure alone may not be sufficient. Patent strength would improve if the design demonstrated a measurable stability, dissolution, manufacturing, or clinical-use advantage.

Does a methocarbamol-aspirin product have biosimilar competition risk?

No. Biosimilar rules apply to biological products. Methocarbamol and aspirin are small-molecule drugs, so competition would arise through generic and, potentially, 505(b)(2) pathways.

What packaging is best for a commercial methocarbamol-aspirin product?

Alu-Alu blister packaging provides strong moisture protection. A sealed HDPE bottle with a desiccant can also be suitable if stability data support the configuration and the product is intended for multidose pharmacy dispensing.

References

1. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.-c). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/drug-approvals-and-databases/product-specific-guidances-generic-drug-development

4. U.S. Food and Drug Administration. (n.d.-d). DailyMed: Current medication labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

5. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP Convention.

6. U.S. Food and Drug Administration. (2016). Guidance for industry: ANDAs for certain highly purified synthetic drug substances. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-drug-substances